U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H22N2O3
Molecular Weight 338.4003
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NOLASIBAN

SMILES

CO\N=C1\C[C@@H](CO)N(C1)C(=O)C2=CC=C(C=C2)C3=C(C)C=CC=C3

InChI

InChIKey=OLUJSZLBWZWGJT-HGBKYHTQSA-N
InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H22N2O3
Molecular Weight 338.4003
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Erlosiban (OBE-001 or Nolasiban) is an oral oxytocin receptor antagonist. Erlosiban inhibits myometrium contractions and inflammation elicited by oxytocin. Erlosiban has the potential to decrease contractions and improve uterine blood flow hence enhancing the receptivity of the endometrium to embryo implantation. This may increase the rates of successful implantation, clinical pregnancy, and live-births among patients undergoing ART, or more specifically IVF procedures.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P30559
Gene ID: 5021.0
Gene Symbol: OXTR
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F(2α)-induced Contractions and Inflammatory Responses in Human Myometrium.
2019 Apr 8
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Phase III trials: 900 mg nolasiban as a single dose increased ongoing pregnancy and live birth rates
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:27:01 GMT 2023
Edited
by admin
on Fri Dec 15 17:27:01 GMT 2023
Record UNII
3765U8A1EC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NOLASIBAN
INN   WHO-DD  
INN  
Official Name English
nolasiban [INN]
Common Name English
Nolasiban [WHO-DD]
Common Name English
OBE-001
Code English
OBE001
Code English
((2S,4Z)-2-(HYDROXYMETHYL)-4-(METHOXYIMINO)PYRROLIDIN-1-YL)(2'-METHYL(1,1'-BIPHENYL)-4-YL)METHANONE
Systematic Name English
3-PYRROLIDINONE, 5-(HYDROXYMETHYL)-1-((2'-METHYL(1,1'-BIPHENYL)-4-YL)CARBONYL)-, 3-(O-METHYLOXIME), (3Z,5S)-
Systematic Name English
ERLOSIBAN
Common Name English
Code System Code Type Description
SMS_ID
100000176871
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
INN
10026
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
FDA UNII
3765U8A1EC
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
PUBCHEM
52947354
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
NCI_THESAURUS
C166647
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
CAS
1477482-19-1
Created by admin on Fri Dec 15 17:27:01 GMT 2023 , Edited by admin on Fri Dec 15 17:27:01 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY